Doxorubicin + Durvalumab + Ifosfamide

This entry describes a potential drug combination of durvalumab, doxorubicin, and ifosfamide. According to the search results, this specific three-drug combination is not mentioned as being used together in clinical practice or trials. Doxorubicin and Ifosfamide are commonly used together as a chemotherapy combination for soft tissue sarcomas. This combination has demonstrated higher response rates compared to doxorubicin alone and is administered intravenously, typically with mesna to prevent bladder toxicity. Dosing regimens and cycle frequencies vary, and significant toxicity, particularly myelosuppression, is associated with this combination. Durvalumab is an anti-PD-L1 antibody approved for use in mismatch repair deficient (dMMR) advanced endometrial cancers, where it has shown significant objective response rates. It functions by blocking the interaction of PD-L1 with PD-1 to enhance anti-tumor T-cell responses. The search results suggest that the combination of chemotherapy (doxorubicin + ifosfamide) with immunotherapy (durvalumab) could represent an investigational approach, although specific information regarding trials or use of this exact three-drug combination was not found.